ArticleScientific reports2026
Streptomyces tyrfis sp. nov., an actinobacterium isolated from Thai peat swamp forest soil and its promising secondary metabolites.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bioprospecting of cultivable actinobacteria from tropical peat swamp forest soil reveals Streptomyces with potent antimicrobial activity.Antonie van Leeuwenhoek · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
An actinomycete strain, PTD5-9T, was isolated from peat swamp forest soil in Narathiwat Province, Thailand. Chemotaxonomic features and phylogenetic analysis based on the 16S rRNA gene sequence placed this strain within the genus Streptomyces. It exhibited the highest sequence similarity to Streptomyces gelaticus NRRL B-2928ᵀ (99.38%) and Streptomyces sanglieri NBRC 100784ᵀ (99.31%). However, the average nucleotide identity based on MUMmer (ANIm) values (88.48–88.56%), the average amino acid identity (84.37–84.97%), and digital DNA–DNA hybridization (dDDH) estimates (31.2–36.5%) were significantly below the accepted thresholds for species demarcation, supporting its classification as a new species within the genus. Accordingly, the name Streptomyces tyrfis sp. nov. is proposed. The crude extract derived from the culture broth of strain PTD5-9ᵀ exhibited potent antibacterial activity against Gram-positive bacteria (MIC ≤ 250 µg/mL). Subsequent chemical analysis led to the identification of ten bioactive secondary metabolites: isocycloheximide (1), (2R,4S,6E)-anhydrocycloheximide (2), actiphenol (3), (−)-phenatic acid A (4), 8-O-methyltetrangomycin (5), 8-O-methylrabelomycin (6), 4-hydroxy-8-O-methylrabelomycin (7), tetrangulol methyl ether (also known as X-14881 E) (8), (−)-elmonin (9), and 2-phenylacetamide (10). Among these, compounds 3, 6, 7, and 8, which were isolated in sufficient quantities, exhibited notable inhibitory activity against Mycobacterium tuberculosis, with MIC values ranging from 3.13 to 25.0 µg/mL. Furthermore, compounds 6, 7, and 8 demonstrated pronounced cytotoxicity against human small cell lung cancer (NCI-H187) cells (IC₅₀: 1.10–7.80 µM), and against human breast cancer (MCF-7) cells (IC₅₀: 1.21–24.6 µM).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.